Breast Cancer Care Plan for High-Risk Ashkenazi Women
This paper presents a breast cancer care plan for a 31-year-old woman of Ashkenazi Jewish descent whose mother carries a BRCA gene mutation. The paper identifies the pathological basis of hereditary breast cancer, outlines a plan of care that includes genetic counseling, screening, and chemoprevention, and examines the role of patient-care technologies such as point-of-care testing, Electronic Health Records, and Bar Coding Medication Administration. It also applies critical thinking to the patient's genetic and psychological risk profile and grounds all recommendations in current evidence-based research on BRCA mutations in Ashkenazi Jewish populations.
- Introduction: Overview of patient scenario and paper scope
- Pathology Identification and Risk Factors: BRCA mutations and Ashkenazi Jewish breast cancer risk
- Development of the Plan of Care: Genetic counseling, screening, and preventive strategies
- Role of Patient-Care Technologies: EHR, point-of-care testing, and medication safety tools
- Critical Thinking in Data Analysis and Interpretation: Evaluating genetic, personal, and psychological risk factors
- Evidence-Based Analysis: Research on BRCA mutations and lifestyle interventions
- Conclusion: Holistic, evidence-based approach to long-term care
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper consistently ties clinical recommendations back to the patient's specific genetic and ethnic background, grounding each decision in the Ashkenazi Jewish BRCA context rather than making generic recommendations.
- It integrates multiple dimensions of care — genetic, technological, psychological, and lifestyle — demonstrating a holistic nursing perspective.
- Citations are current and directly relevant, with peer-reviewed sources specifically addressing BRCA mutations in Ashkenazi Jewish populations, lending credibility to the risk assessment.
Key academic technique demonstrated
The paper models evidence-based clinical reasoning by moving systematically from pathology identification through care planning to technology application, using each section to build toward a comprehensive, individualized care plan. This structure reflects the nursing process (assessment → planning → intervention → evaluation) even without labeling it explicitly.
Structure breakdown
The paper opens with a brief introduction framing the patient scenario, then proceeds through six focused sections: risk identification, plan of care, patient-care technologies, critical thinking, evidence-based analysis, and a synthesizing conclusion. Each section is concise and targeted, making it well-suited as a structured case-study response. The references section cites three recent APA-formatted sources.
Introduction
This paper addresses the case of a 31-year-old woman of Ashkenazi Jewish descent who is concerned about her risk of developing breast cancer, given her mother's diagnosis and known BRCA gene mutation. An effective response to her situation requires integrating genetic risk factors, patient-care technologies, and evidence-based practice into a comprehensive, individualized plan of care.
Pathology Identification and Risk Factors
Breast cancer is a malignant tumor originating in breast tissue and presents a significant concern for women with a family history of the disease. The risk is notably higher in individuals of Ashkenazi Jewish descent, particularly those with a BRCA gene mutation, as seen in the patient's mother (Roberts et al., 2023). BRCA1 and BRCA2 mutations significantly increase the risk of developing both breast and ovarian cancers (Lieberman et al., 2022).
The patient's Ashkenazi heritage and family history place her at elevated risk, which means careful monitoring and preventive strategies must be considered. Research has further shown that polygenic risk scores developed in White European populations may not be well-calibrated for women of Ashkenazi Jewish descent, underscoring the importance of ethnicity-specific risk assessment (Roberts et al., 2023).
Development of the Plan of Care
The plan of care for this patient should include genetic counseling and testing for BRCA mutations. If results are positive, options such as regular enhanced screening, preventive (prophylactic) surgery, or chemoprevention should be discussed and considered. Lifestyle modifications — including maintaining a healthy weight, engaging in regular physical activity, and following a balanced diet — and close monitoring for early detection should also be incorporated into the care plan (Haddad, 2020).
Role of Patient-Care Technologies
Several patient-care technologies play an important role in managing this patient's care. Point-of-care testing allows for rapid genetic testing for BRCA mutations, providing timely information to support clinical decision-making. Computer Provider Order Entry (CPOE) supports the accurate ordering of tests and treatments, minimizing the risk of errors.
Bar Coding Medication Administration (BCMA) ensures that the correct patient receives the right medication and dosage — a safeguard that is especially important in chemoprevention or active treatment scenarios. Electronic Medical Records (EMR) and Electronic Health Records (EHR) systems provide comprehensive, accessible patient data that facilitate continuity of care and informed decision-making. These systems are essential for tracking the patient's health status, test results, and response to any interventions over time.
Conclusion
In this case study, the integration of genetic risk factors, patient-care technologies, and a holistic approach to the patient's physical and psychological well-being are essential components of effective care. The use of evidence-based practice, supported by current research and interdisciplinary insights, guides the development of a comprehensive plan of care. This approach addresses the immediate concerns surrounding breast cancer risk while also considering the patient's long-term health and quality of life.
References
Haddad, C. F. (2020). Hereditary breast cancer: Review and current approach. Mastology, 30, 1–11.
Lieberman, S., Chen-Shtoyerman, R., Levi, Z., Shkedi-Rafid, S., Zuckerman, S., Bernstein-Molho, R., ... & Goldberg, Y. (2022). Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews. Breast Cancer Research and Treatment, 193(1), 217–224.
Roberts, E., van Veen, E. M., Byers, H., Barnett-Griness, O., Gronich, N., Lejbkowicz, F., ... & Evans, D. G. (2023). Breast cancer polygenic risk scores derived in White European populations are not calibrated for women of Ashkenazi Jewish descent. Genetics in Medicine, 100846.
Always verify citation format against your institution’s current style guide requirements.